Five Prime Therapeutics Inc Quick Ratio (FPRX) starting from the fourth quarter 2020 to fourth quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Five Prime Therapeutics Inc   (NASDAQ: FPRX)

Five Prime Therapeutics Inc 's Quick Ratio

FPRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Five Prime Therapeutics Inc 's Cash & cash equivalent grew by 157.93 % in the Q4 2020 sequentially, while Current Liabilities decreased, this led to improvement in Five Prime Therapeutics Inc 's Quick Ratio to 12.95, above Five Prime Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 148 other companies have achieved higher Quick Ratio than Five Prime Therapeutics Inc in fourth quarter 2020. While Quick Ratio total ranking has improved so far during the Q4 2020 to 566, from total ranking in the third quarter 2020 at 725.

Explain Quick Ratio?
How much Cash & cash equivalents FPRX´s has?
What are FPRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FPRX Quick Ratio (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4
Y / Y Current Liabilities Change -3.65 % -19.16 % -40.28 % -20.2 % -16.24 %
Y / Y Cash & cash equivalent Change 83.69 % -40.12 % -40.66 % -40.44 % -42.11 %
Quick Ratio MRQ 12.95 4.83 6.35 7.35 6.79
FPRX's Total Ranking # 566 # 725 # 514 # 375 # 491
Seq. Current Liabilities Change -3.74 % 15.2 % 4.14 % -16.57 % -19.24 %
Seq. Cash & cash equivalent Change 157.93 % -12.35 % -9.97 % -9.75 % -15.92 %



Quick Ratio fourth quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 149
Healthcare Sector # 230
Overall Market # 566


Quick Ratio Statistics
High Average Low
15.03 8.34 3.21
(Sep 30 2016)   (Dec 31 2012)




Financial Statements
Five Prime Therapeutics Inc 's Current Liabilities $ 22 Millions Visit FPRX's Balance sheet
Five Prime Therapeutics Inc 's Cash & cash equivalent $ 287 Millions Visit FPRX's Balance sheet
Source of FPRX's Sales Visit FPRX's Sales by Geography


Cumulative Five Prime Therapeutics Inc 's Quick Ratio

FPRX's Quick Ratio for the trailling 12 Months

FPRX Quick Ratio

 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth -22.6 % -24.9 % -27.16 % -14.06 % -21.16 %
Y / Y Cash & cash equivalent TTM Growth -15.96 % -40.93 % -41.45 % -40.95 % -40.52 %
Quick Ratio TTM 7.9 6.28 6.73 6.69 7.27
Total Ranking TTM # 185 # 4289 # 4269 # 335 # 4253
Seq. Current Liabilities TTM Growth -0.98 % -6.02 % -12.95 % -4.46 % -3.93 %
Seq. Cash & cash equivalent TTM Growth 24.42 % -12.22 % -12.48 % -12.08 % -12.54 %

Quick ratio ranking by company, industry and sector >> Back to FPRX Financial Strength Comparisons >> Go to Compare FPRX Quick Ratio to its Competitors

On the trailing twelve months basis FPRX Cash & cash equivalent soared by 83.69 % in Q4 2020 year on year, while Current Liabilities decreased to $22 millions, this led to increase in in Five Prime Therapeutics Inc 's Quick Ratio to 7.9, Quick Ratio remained below FPRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Quick Ratio than Five Prime Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 185, from total ranking during the twelve months ending third quarter 2020 at 4289.

Explain Quick Ratio?
How much Cash & cash equivalents FPRX´s has?
What are FPRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 59
Healthcare Sector # 88
Within the Market # 185


trailing twelve months Quick Ratio Statistics
High Average Low
10.48 8.33 6.28
(Jun 30 2017)   (Sep 30 2020)




Companies with similar Quick Ratio in the quarter ending Dec 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2020 MRQ Cash & cash equivalentDec 31 2020 MRQ Current Liabilities
Eledon Pharmaceuticals Inc   35.17 $ 114.195  Millions$ 3.247  Millions
Lantern Pharma Inc   34.82 $ 38.458  Millions$ 1.105  Millions
89bio Inc   34.52 $ 280.039  Millions$ 8.113  Millions
Cytokinetics Incorporated  33.86 $ 962.139  Millions$ 28.414  Millions
Oric Pharmaceuticals Inc   32.61 $ 293.600  Millions$ 9.002  Millions
Kronos Bio Inc   32.13 $ 413.061  Millions$ 12.856  Millions
Sigilon Therapeutics Inc   32.12 $ 202.229  Millions$ 6.296  Millions
Dyne Therapeutics Inc   31.49 $ 345.314  Millions$ 10.967  Millions
Sage Therapeutics Inc   31.24 $ 2,099.549  Millions$ 67.204  Millions
Arena Pharmaceuticals Inc   31.23 $ 1,104.041  Millions$ 35.351  Millions
Scorpius Holdings inc   30.57 $ 111.774  Millions$ 3.657  Millions
Zomedica Corp   30.56 $ 61.992  Millions$ 2.029  Millions
Repare Therapeutics Inc   30.30 $ 333.710  Millions$ 11.014  Millions
Damora Therapeutics Inc   29.39 $ 163.582  Millions$ 5.566  Millions
Cocrystal Pharma Inc   28.97 $ 33.060  Millions$ 1.141  Millions
Annexon Inc   28.79 $ 351.206  Millions$ 12.198  Millions
Akouos inc   28.76 $ 308.010  Millions$ 10.709  Millions
Essa Pharma inc   28.49 $ 74.501  Millions$ 2.615  Millions
Viela Bio Inc   28.47 $ 367.687  Millions$ 12.917  Millions
Rain Enhancement Technologies Holdco Inc   27.35 $ 58.885  Millions$ 2.153  Millions
Tff Pharmaceuticals Inc  27.20 $ 35.301  Millions$ 1.298  Millions
Connect Biopharma Holdings Limited  26.58 $ 154.803  Millions$ 5.823  Millions
Arvinas Inc   26.50 $ 688.531  Millions$ 25.982  Millions
Longboard Pharmaceuticals Inc   26.48 $ 55.316  Millions$ 2.089  Millions
Oncorus Inc   26.11 $ 130.305  Millions$ 4.991  Millions
Forte Biosciences Inc   26.01 $ 58.765  Millions$ 2.259  Millions
Dogwood Therapeutics inc   25.84 $ 29.795  Millions$ 1.153  Millions
Vera Therapeutics Inc   25.51 $ 53.740  Millions$ 2.107  Millions
Pandion Therapeutics Inc   24.83 $ 219.891  Millions$ 8.856  Millions
Neurogene Inc   24.41 $ 192.556  Millions$ 7.889  Millions

Date modified: 2026-06-22T14:32:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.